PDF(Pubmed)
Abstract：
UNASSIGNED: Palmoplantar pustulosis (PPP) is a complex inflammatory skin disease. Currently, no standardized treatments exist, and traditional systemic therapies often display limited effectiveness and substantial adverse effects. Biologics, however, have shown potential for enhanced clinical outcomes in psoriasis patients, thereby prompting this investigation into their applicability in PPP treatment.
UNASSIGNED: This study constitutes the first comprehensive review to assess the effectiveness and underlying mechanisms of biologics for PPP.
UNASSIGNED: We conducted a PubMed search to identify studies on biologics for PPP from 1992 onward. The review focused on assessing the efficacy of biologics targeting cytokines like IL-1, IL-8, IL-17, IL-12/23, IL-36, and TNF-α.
UNASSIGNED: Biologics for PPP are generally less effective than for psoriasis. Secukinumab and guselkumab, IL-17 and IL-23 inhibitors respectively, have shown better results compared to other biologics in trials. However, the effectiveness of other biologics remains uncertain due to limited data.
UNASSIGNED: More research is needed to find effective treatments for PPP, and selecting the right biologic for each patient is challenging.
UNASSIGNED: This study constitutes the first comprehensive review to assess the effectiveness and underlying mechanisms of biologics for PPP.
UNASSIGNED: We conducted a PubMed search to identify studies on biologics for PPP from 1992 onward. The review focused on assessing the efficacy of biologics targeting cytokines like IL-1, IL-8, IL-17, IL-12/23, IL-36, and TNF-α.
UNASSIGNED: Biologics for PPP are generally less effective than for psoriasis. Secukinumab and guselkumab, IL-17 and IL-23 inhibitors respectively, have shown better results compared to other biologics in trials. However, the effectiveness of other biologics remains uncertain due to limited data.
UNASSIGNED: More research is needed to find effective treatments for PPP, and selecting the right biologic for each patient is challenging.
摘要：
■掌plant脓疱病（PPP）是一种复杂的炎症性皮肤病。目前,没有标准化的治疗方法，和传统的全身疗法往往显示有限的有效性和实质性的不良反应。生物制品,然而,已显示出增强银屑病患者临床结局的潜力，从而促使这项调查对它们在PPP治疗中的适用性进行研究。
■这项研究是评估PPP生物制剂有效性和潜在机制的第一次全面审查。
■我们进行了PubMed搜索，以确定从1992年开始的PPP生物制剂研究。该综述集中于评估生物制剂靶向细胞因子如IL-1，IL-8，IL-17，IL-12/23，IL-36和TNF-α的功效。
■PPP的生物制剂通常不如牛皮癣有效。Secukinumab和guselkumab，IL-17和IL-23抑制剂与其他生物制剂相比，在试验中显示出更好的结果。然而,由于数据有限，其他生物制剂的有效性仍不确定。
■需要更多的研究来寻找PPP的有效治疗方法，为每个患者选择合适的生物制剂是具有挑战性的。
■这项研究是评估PPP生物制剂有效性和潜在机制的第一次全面审查。
■我们进行了PubMed搜索，以确定从1992年开始的PPP生物制剂研究。该综述集中于评估生物制剂靶向细胞因子如IL-1，IL-8，IL-17，IL-12/23，IL-36和TNF-α的功效。
■PPP的生物制剂通常不如牛皮癣有效。Secukinumab和guselkumab，IL-17和IL-23抑制剂与其他生物制剂相比，在试验中显示出更好的结果。然而,由于数据有限，其他生物制剂的有效性仍不确定。
■需要更多的研究来寻找PPP的有效治疗方法，为每个患者选择合适的生物制剂是具有挑战性的。
